Sanofi gets genetic heart disease projects through alliance with MyoKardia; MyoKardia regains rights
Executive Summary
Enhancing its Sunrise open innovation initiative, which aims to create risk-sharing relationships surrounding early-stage opportunities, Sanofi partnered with cardiovascular disease-focused start-up MyoKardia Inc. to develop targeted therapies for heritable heart diseases called cardiomyopathies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice